Benitec Biopharma Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BNTC Nasdaq 2830 benitec.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Benitec Biopharma Inc.

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - May 14th, 2026 6:00 am
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - Apr 28th, 2026 5:00 am
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - Mar 10th, 2026 5:00 am
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Mar 9th, 2026 5:00 am
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference - Feb 23rd, 2026 5:00 am
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Feb 14th, 2026 6:27 am
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update - Feb 12th, 2026 6:30 am
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - Jan 11th, 2026 6:00 am
Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect? - Dec 24th, 2025 7:55 am
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know - Dec 5th, 2025 7:55 am
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) - Dec 3rd, 2025 7:35 am
Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment - Nov 18th, 2025 4:16 am
Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership - Nov 18th, 2025 3:27 am
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - Nov 14th, 2025 3:00 pm
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others - Nov 12th, 2025 7:45 am
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - Nov 5th, 2025 10:19 pm
Benitec Biopharma Inc. Announces Proposed Public Offering - Nov 5th, 2025 2:43 pm
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - Nov 3rd, 2025 5:10 am
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors - Nov 3rd, 2025 5:00 am
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - Nov 2nd, 2025 5:00 pm